• About Amgen
  • Science
  • Corporate Giving
  • Site Map
  • Search
  • Privacy & Terms
  • Contact Us
Amgen
  • Patients
  • Medical Professionals
  • Partners
  • Investors
  • Careers
  • Media
  • print
  • mail
  • Home
  • Reimbursement Connection®
  • Amgen™ Oncology Assistance

  • Overview
  • Amgen™ Oncology Assistance
  • Aranesp®
    (darbepoetin alfa)
  • Neulasta®
    (pegfilgrastim)
  • NEUPOGEN®
    (Filgrastim)
  • Nplate™
    (romiplostim)
  • EPOGEN®
    (Epoetin alfa)
  • Sensipar®
    (cinacalcet)
  • Enbrel®
    (etanercept)
  • Vectibix®
    (panitumumab)
Introducing Amgen™ Oncology Assistance

A commitment to unprecedented patient access

  • In our unwavering patient focus, Amgen is committed to serving the best interests of patients
  • Our goal is to have the most comprehensive oncology access program in the industry, and we’re starting with Amgen™ Oncology Assistance
  • Amgen™ Oncology Assistance is a multifaceted array of assistance programs that will include a “cap” on out-of-pocket drug expenses for cancer patients receiving Vectibix™ (panitumumab)

Access Made Easy Through a Single Gateway

Physicians and patients can call 1.800.272.9376, where a specialist will assess their case and direct them to the appropriate component of the program.

Amgen™ Oncology Assistance

 

  • Related Links
  • AmgenOncology.com
  • Reimbursement Connection
  • Colon Cancer Alliance
  • Colorectal CareLine
  • PPARx
  • Rx Assist
footer